Mustargen (Mechlorethamine) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Mustargen is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat Hodgkin lymphoma in stages III and IV, chronic lymphocytic leukemia (CLL), mycosis fungoides, lymphosarcoma, and chronic myelocytic leukemia (CML). Mustargen is often used as part of a chemotherapy regimen such as the Stanford V. Mustargen is also known by the drug names mechlorethamine, chlormethine, and mustine.

Mustargen is an anticancer drug and a member of a class of drugs called alkylating agents. Mustargen is believed to work by preventing the production of DNA in cells, thereby blocking cell division.

How do I take it?
Mustargen is given as an intravenous infusion during chemotherapy.

Side effects
The FDA-approved label for Mustargen lists common side effects including nausea, vomiting, weakness, loss of appetite, hair loss, ringing in the ears, and low blood cell counts. Injection site reactions are common and painful side effects of taking Mustargen.

Rare but serious side effects listed for Mustargen include abnormal bleeding, fetal harm in pregnant women, infertility in men and women, hypersensitivity reactions, and increased risk for developing another type of cancer.

For more details about this treatment, visit:

Mustargen — RxList

Chemotherapy for Hodgkin Lymphoma — American Cancer Society

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in